Stempoint Capital’s Nektar Therapeutics NKTR Stock Holding History

Stempoint Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-178,274	Closed	-$7.54M	–	107
2025 Q4	$7.54M	Buy	178,274 +125,073	+235%	+$7M	1.29%	22
2025 Q3	$3.03M	Buy	+53,201	New	+$1.76M	0.61%	39

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stempoint Capital's NKTR Position: Q1 2026 in Review

Stempoint Capital sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 178,274 shares — an estimated $7.54M sold.

Stempoint Capital first reported a position in NKTR in Q3 2025 and held it in 2 quarters. The position peaked at $7.54M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Stempoint Capital reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 178,274 Nektar Therapeutics shares in Q1 2026, an estimated $7.54M.
Stempoint Capital first reported a position in Nektar Therapeutics in Q3 2025 and held it in 2 quarters.
Stempoint Capital's Nektar Therapeutics position peaked at $7.54M in Q4 2025.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.